Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Industry, Sector and Symbol
Stock Exchange TSE
Industry Technical & System Software
Sub-IndustryN/A
SectorComputer and Technology
SymbolTSE:AUP
CUSIPN/A
Phone+1-250-7084272
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-45,241.38%
Return on Equity-30.41%
Return on Assets-25.82%
Miscellaneous
EmployeesN/A
Outstanding Shares84,200,000
Market CapC$596.22
Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."
How were Aurinia Pharmaceuticals' earnings last quarter?
Aurinia Pharmaceuticals Inc (TSE:AUP) released its earnings results on Thursday, May, 10th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The business earned $0.04 million during the quarter, compared to analyst estimates of $0.07 million. Aurinia Pharmaceuticals had a negative net margin of 45,241.38% and a negative return on equity of 30.41%. View Aurinia Pharmaceuticals' Earnings History.
When is Aurinia Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Iress (IRE), Computer Modelling Group (CMG), GB Group (GBG), Emis Group (EMIS), Wandisco (WAND), SDL (SDL), Microgen (MCGN), Absolute Software (ABT), Dotdigital Group (DOTD), TECSYS (TCS), Ideagen (IDEA), iSentia Group (ISD), Smart Parking (SPZ), IDOX (IDOX) and Gresham Technologies (GHT).
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 60)
- Mr. Michael R. Martin, Co-Founder & COO
- Mr. Dennis Bourgeault C.A., CFO & Sec.
- Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
- Dr. Neil Solomons M.D., Chief Medical Officer
Has Aurinia Pharmaceuticals been receiving favorable news coverage?
Media coverage about AUP stock has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a news sentiment score of 0.10 on Accern's scale. They also gave media coverage about the company an impact score of 45.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Aurinia Pharmaceuticals?
Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of AUP stock can currently be purchased for approximately C$7.52.
How big of a company is Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals has a market capitalization of C$596.22 million.
How can I contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.
MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days.
